Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Generic Biktarvy is indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg. Lupin has received tentative approval from the Food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback